Clinical Trials
27 trialsNCT07596212 2026-05-19
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
University of Illinois at Chicago
Phase 1/2 Not yet recruiting
NCT05827081 2026-05-14
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT04569747 2026-04-02
ADEPT
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT07158021 2026-02-13
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT01674140 2026-02-10
e3
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT05122377 2026-01-06
RWE About QOL and Compliance of Patients With OFS in China
Fudan University
Completed
NCT07159451 2025-12-01
POP-ELA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT03944434 2025-02-26
FACILE
Fondazione Sandro Pitigliani
Phase 2 Active not recruiting
NCT03900637 2024-07-31
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate
Seoul National University Hospital
Phase 2 Active not recruiting
NCT02344472 2024-06-04
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
Phase 3 Active not recruiting
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT02941926 2023-10-24
COMPLEEMENT-1
Novartis
Phase 3 Completed
NCT02914158 2023-01-17
ASPAIT
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Unknown
NCT01989780 2022-08-04
BOOSTER
Japan Breast Cancer Research Group
Phase 2 Completed
NCT02344550 2020-07-30
LEO
Asan Medical Center
Phase 2 Completed
NCT02592746 2019-04-08
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
Samsung Medical Center
Phase 2 Unknown
NCT02689921 2018-09-28
NEOADAPT
Midwestern Regional Medical Center
Phase 2 Unknown
NCT03497702 2018-04-13
NeoChAI
National Cancer Center, Korea
Phase 2 Unknown
NCT02980965 2017-11-13
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
Fudan University
Phase 3 Completed
NCT02134977 2016-10-18
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"
Takeda
Completed
NCT00903162 2016-04-18
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02154139 2016-02-17
Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"
Takeda
Completed
NCT00002580 2013-11-06
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002582 2013-08-02
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00498901 2013-05-09
Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer
University of Washington
Phase 2 Terminated